Cargando…

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data

OBJECTIVE: To evaluate utilization of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF). METHODS: We analyzed the MarketScan databases for the period 1/1/2021 to 6/30/2022. Validat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alonso, Alvaro, Morris, Alanna A., Naimi, Ashley I., Alam, Aniqa B., Li, Linzi, Subramanya, Vinita, Chen, Lin Yee, Lutsey, Pamela L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508822/ https://www.ncbi.nlm.nih.gov/pubmed/37732232 http://dx.doi.org/10.1101/2023.09.08.23295280

Ejemplares similares

Associations of Atrial Fibrillation with Mild Cognitive Impairment and Dementia: An Investigation Using SPRINT Research Materials
por: Alam, Aniqa B., et al.
Publicado: (2022)

Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation
por: Chen, Nemin, et al.
Publicado: (2020)

Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database
por: Subramanya, Vinita, et al.
Publicado: (2021)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Circulating Magnesium and Risk of Major Adverse Cardiac Events among Patients with Atrial Fibrillation in the ARIC Cohort
por: Li, Linzi, et al.
Publicado: (2023)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

Response to cardiac resynchronization therapy and treatment with ARNi and iSGLT2
por: Fonderico, C, et al.
Publicado: (2023)

Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation
por: O’Neal, Wesley T., et al.
Publicado: (2019)

Association of physical activity with the incidence of atrial fibrillation in persons > 65 years old: the Atherosclerosis Risk in Communities (ARIC) study
por: Fletcher, Grace, et al.
Publicado: (2022)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

Low Serum Magnesium is Associated with Incident Dementia in the ARIC-NCS Cohort
por: Alam, Aniqa B., et al.
Publicado: (2020)

Associations of Serum Magnesium with Brain Morphology and Subclinical Cerebrovascular Disease: The Atherosclerosis Risk in Communities-Neurocognitive Study
por: Alam, Aniqa B., et al.
Publicado: (2021)

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
por: Yan, Yuling, et al.
Publicado: (2021)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

My gratitude for Arny's friendship with me
por: Õmura, Satoshi
Publicado: (2021)

Association of household income and adverse outcomes in patients with atrial fibrillation
por: LaRosa, Anna Rose, et al.
Publicado: (2020)

ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations
por: Niemiec, Rafał, et al.
Publicado: (2022)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants
por: Shao, Iris Yuefan, et al.
Publicado: (2021)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

Impact of Atrial Fibrillation on Healthcare Utilization in the Community: The Atherosclerosis Risk in Communities Study
por: Bengtson, Lindsay G. S., et al.
Publicado: (2014)

Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation
por: O'Neal, Wesley T., et al.
Publicado: (2018)

Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
por: Chen, Nemin, et al.
Publicado: (2018)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

ARNi: A Novel Approach to Counteract Cardiovascular Diseases
por: Volpe, Massimo, et al.
Publicado: (2019)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Association of Atrial Fibrillation With Incidence of Extracranial Systemic Embolic Events: The ARIC Study
por: Shi, Mengyuan, et al.
Publicado: (2020)

Editorial for “Biointelligent manufacturing in Memorium of Arnold (Arny) L. Demain”
por: Gao, Qiang, et al.
Publicado: (2022)

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation
por: Bode, David, et al.
Publicado: (2021)

Joint Associations of Obesity and NT‐proBNP With the Incidence of Atrial Fibrillation in the ARIC Study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2019)

Lessons from the lab: what I learned from Arnie Levine
por: Freedman-Cass, Deborah
Publicado: (2019)

A paean to Arnie Levine on the occasion of his 80th birthday
por: Hinds, Philip W
Publicado: (2019)

Trends of ARNI and Other Heart Failure Medication Use in Older Adults
por: Lee, Yu-Chien, et al.
Publicado: (2021)

Reply to Letter to the Editor: “Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?”
por: Dindaş, Ferhat, et al.
Publicado: (2022)

Association of arterial stiffness with incident atrial fibrillation: a cohort study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2021)

Circulating Fibroblast Growth Factor‐23 and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study
por: Alonso, Alvaro, et al.
Publicado: (2014)

Monitoring the Effectiveness and Safety of ARNI vs. Angiotensin Receptor Blocker by Frailty Status
por: Kim, Dae, et al.
Publicado: (2021)

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

Association of Left Atrial Enlargement and Atrial Fibrillation With Cognitive Function and Decline: The ARIC‐NCS
por: Zhang, Michael J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t25eaar4rg6v2740sq50rdmofn